Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 16, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, May 15, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Uy Ear Maintained (ARQT) at Strong Buy with Increased Target to $18 on, May 15th, 2024
Uy Ear of Mizuho, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Increased Target from $17 to $18 on, May 15th, 2024.
Uy has made no other calls on ARQT in the last 4 months.
There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, all agrees with Uy's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jonathan Block of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Wednesday, February 28th, 2024
